RxDoctor Payments Data

Donna Oneill, MD

Infectious Disease · Jackson, MINPI 1174534994

Payments from drug & device makers

$736in general payments, 2019–2025

Across 40 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$201
  • Biohaven Pharmaceuticals, Inc.$100
  • Gilead$95
  • Merck$91
  • Melinta Therapeutics, LLC$67
  • Eisai Inc.$55
  • plus $127 from 5 others

What the payments were for

  • Food & beverage$72098%
  • Education$162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$736 in reported general payments places this provider in the 65th percentile of 257 infectious disease providers in Michigan.

See all infectious disease providers in Michigan

Medicare billing

Part B allowed, 2024
$1,449,516
Medicare patients
267
Services billed
356,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen40$173,012
BiktarvyBictegrav/Emtricit/Tenofov Ala27$106,612
JulucaDolutegravir/Rilpivirine29$93,206
XolairOmalizumab26$90,022
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$58,310
Vancomycin Hcl45$5,315
Daptomycin12$2,501
Linezolid18$2,343
Rifampin15$1,437
CefuroximeCefuroxime Axetil41$1,325
Estradiol11$1,101
Minocycline Hcl56$924
Fluconazole60$843
Doxycycline Hyclate93$831
Clarithromycin15$823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy$95$279,62467 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 257 infectious disease providers in Michigan.

Other infectious disease in Jackson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →